A5083634575- Chemotherapy-induced cardiotoxicity and mitigation
- Cancer Treatment and Pharmacology
- Cardiovascular Health and Disease Prevention
- Immune cells in cancer
- Coronary Interventions and Diagnostics
- Galectins and Cancer Biology
- Heart Failure Treatment and Management
- Cardiovascular Disease and Adiposity
- Brain Metastases and Treatment
- Atherosclerosis and Cardiovascular Diseases
- Angiogenesis and VEGF in Cancer
- Chemotherapy-induced organ toxicity mitigation
- Cardiac Imaging and Diagnostics
- Takotsubo Cardiomyopathy and Associated Phenomena
- Adipokines, Inflammation, and Metabolic Diseases
- Liver Disease Diagnosis and Treatment
- Atrial Fibrillation Management and Outcomes
Moscow State University of Medicine and Dentistry
2019-2023
It is known that the advances in cancer treatment leading to increased survival malignant neoplasms, entail a variety of adverse cardiovascular toxic effects can be quite serious and even potentially fatal. An important component influences degree cardiotoxicity risk patient’s clinical functional state history at time diagnosis. This information used practice for screening evaluation patient with neoplasm before start antitumor therapy. After completion cardiotoxic therapy, as well during...
Introduction. Cancer occupies one of the leading positions in list most common death causes world. The widespread use chemo-, targeted, immune and radiation therapy clinical practice has increased survival cancer patients. However, incidence cardiotoxic complications antitumor significantly, they may manifest themselves many years after onset remission. Brief description. We present a case premature coronary artery disease (CAD) 40-year-old male patient, who underwent multiagent chemotherapy...
Cancer is the second leading cause of mortality in world, only to cardiovascular diseases. Simultaneously cancer has been steadily decreasing due development new chemotherapy and targeted drugs improvement existing treatment protocols. Improving prognosis patients leads an unexpected result - more are faced with side effects treatment. Cardiotoxicity, including arrhythmia, become a significant factor reduce effectiveness patient’s Atrial fibrillation frequent persistent rhythm disorder,...
Aim . To search early signs of cardiotoxicity in patients receiving anticancer therapy and evaluate the effectiveness cardioprotection with an angiotensin-converting enzyme inhibitor, beta-blocker myocardial cytoprotector. Material methods The study included 98 high very risk according to Mayo Clinic scale (USA). Cancer hypertension were offered cardioprotective treatment a fixed-dose combination perindopril bisoprolol, concomitant coronary artery disease additionally trimetazidine. divided...
Introduction. Cancer remains one of the most common causes death in world, second only to cardiovascular diseases. The use novel chemotherapeutic and targeted agents has significantly improved prognosis this group patients. However, increased number cardiotoxic complications anticancer therapy, including arrhythmias, particular atrial fibrillation (AF), which negatively affects prognosis. Brief description . purpose article was describe case a 64-yearold woman with central right lung lower...